201 related articles for article (PubMed ID: 36823642)
21. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study.
Yang H; Chen M; Mei Z; Xie C; Zhou Y; Qiu H
Cancer Med; 2021 Jul; 10(13):4282-4290. PubMed ID: 33987959
[TBL] [Abstract][Full Text] [Related]
23. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
[TBL] [Abstract][Full Text] [Related]
24. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.
Lin Y; Qin S; Li Z; Yang H; Fu W; Li S; Chen W; Gao Z; Miao W; Xu H; Zhang Q; Zhao X; Bao J; Li L; Ren Y; Lin C; Jing S; Ma Q; Liang J; Chen G; Zhang H; Zhang Y; Zhou X; Sang Y; Hou Z
JAMA Oncol; 2022 Feb; 8(2):242-250. PubMed ID: 34913959
[TBL] [Abstract][Full Text] [Related]
25. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
26. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
[No Abstract] [Full Text] [Related]
27. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
Xia X; Jiang W; Qi W; Hong B; Zhao W
Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
[TBL] [Abstract][Full Text] [Related]
28. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
Cui Q; Hu Y; Ma D; Liu H
Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
Xia L; Peng J; Lou G; Pan M; Zhou Q; Hu W; Shi H; Wang L; Gao Y; Zhu J; Zhang Y; Sun R; Zhou X; Wang Q; Wu X
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017154
[TBL] [Abstract][Full Text] [Related]
30. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
31. Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study.
He W; Liao L; Hu D; Li B; Wang C; Qiu J; Liao Y; Liu W; Yang Z; Zhang Y; Yuan Y; Li K; Yuan Y; Zheng Y
Ann Transl Med; 2020 Aug; 8(16):1000. PubMed ID: 32953800
[TBL] [Abstract][Full Text] [Related]
32. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
[No Abstract] [Full Text] [Related]
33. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study.
Liang J; Gu W; Jin J; Zhang H; Chen Z; Tang Y; Zhang S; Yang S; Deng Y; Feng W
Ther Adv Med Oncol; 2020; 12():1758835920968472. PubMed ID: 33403012
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
36. Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression.
Wang Z; Huang Y; Long L; Zhou L; Huang Y; Gan L; Pu A; Li S; Xie R
J Ovarian Res; 2021 Jul; 14(1):91. PubMed ID: 34247630
[TBL] [Abstract][Full Text] [Related]
37. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
38. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
[TBL] [Abstract][Full Text] [Related]
39. A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients.
Yang M; Liu X; Zhang C; Liao F; Li Z; Luo X; Sun Y; Chen C
Cancer Manag Res; 2019; 11():8869-8876. PubMed ID: 31632146
[TBL] [Abstract][Full Text] [Related]
40. The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives.
Yang X; Fu C
Arch Gynecol Obstet; 2022 Nov; 306(5):1417-1429. PubMed ID: 35165749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
